PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan

Bektur, C.; Nurgozhin, T.

NUR Home
→
02.National Laboratory Astana
→
Center for Life Sciences
→
Laboratory of Epidemiology and Public Health
→
View Item

Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.

dc.contributor.author	Bektur, C.
dc.contributor.author	Nurgozhin, T.
dc.creator	C., Bektur
dc.date.accessioned	2017-12-13T09:25:28Z
dc.date.available	2017-12-13T09:25:28Z
dc.date.issued	2014-11-01
dc.identifier	DOI:10.1016/j.jval.2014.08.333
dc.identifier.citation	C. Bektur, T. Nurgozhin, PMS17 - Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Pages A773-A774
dc.identifier.issn	10983015
dc.identifier.uri	https://www.sciencedirect.com/science/article/pii/S1098301514022633
dc.identifier.uri	http://nur.nu.edu.kz/handle/123456789/2874
dc.description.abstract	A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC.
dc.relation.ispartof	Value in Health
dc.title	PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan
dc.type	Article
dc.rights.license	Copyright © 2014 Published by Elsevier Inc.
elsevier.identifier.doi	10.1016/j.jval.2014.08.333
elsevier.identifier.eid	1-s2.0-S1098301514022633
elsevier.identifier.pii	S1098-3015(14)02263-3
elsevier.volume	17
elsevier.issue.identifier	7
elsevier.coverdate	2014-11-01
elsevier.coverdisplaydate	November 2014
elsevier.startingpage	A773
elsevier.endingpage	A774
elsevier.openaccess	1
elsevier.openaccessarticle	true
elsevier.openarchivearticle	true
elsevier.openaccessuserlicense	http://www.elsevier.com/open-access/userlicense/1.0/
elsevier.aggregationtype	Journal